schliessen

Filtern

 

Bibliotheken

Citrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis

Citrus flavonoids are polyphenolic compounds with significant biological properties. This review summarizes recent advances in understanding the ability of citrus flavonoids to modulate lipid metabolism, other metabolic parameters related to the metabolic syndrome, and atherosclerosis. Citrus flavon... Full description

Journal Title: Annual review of nutrition 2016-07-17, Vol.36 (1), p.275-299
Main Author: Mulvihill, Erin E
Other Authors: Burke, Amy C , Huff, Murray W
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: United States: Annual Reviews
ID: ISSN: 0199-9885
Link: https://www.ncbi.nlm.nih.gov/pubmed/27146015
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmed_primary_27146015
title: Citrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis
format: Article
creator:
  • Mulvihill, Erin E
  • Burke, Amy C
  • Huff, Murray W
subjects:
  • adipose tissue
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
  • Anti-Obesity Agents - therapeutic use
  • Antioxidants - therapeutic use
  • Atherosclerosis
  • Atherosclerosis - epidemiology
  • Atherosclerosis - etiology
  • Atherosclerosis - prevention & control
  • Bioflavonoids
  • Blood lipoproteins
  • Citrus
  • Citrus - chemistry
  • citrus flavonoids
  • Citrus fruits
  • Diabetes Mellitus, Type 2 - diet therapy
  • Diabetes Mellitus, Type 2 - immunology
  • Diabetes Mellitus, Type 2 - metabolism
  • Diabetes Mellitus, Type 2 - physiopathology
  • Dietary Supplements
  • Flavones
  • Flavonoids
  • Flavonoids - therapeutic use
  • glucose metabolism
  • Health aspects
  • Humans
  • Hyperlipidemias - diet therapy
  • Hyperlipidemias - immunology
  • Hyperlipidemias - metabolism
  • Hyperlipidemias - physiopathology
  • Hypolipidemic Agents - therapeutic use
  • inflammation
  • Insulin Resistance
  • lipid metabolism
  • Lipoproteins
  • Lipoproteins - blood
  • Lipoproteins - metabolism
  • Metabolism
  • Non-alcoholic Fatty Liver Disease - diet therapy
  • Non-alcoholic Fatty Liver Disease - immunology
  • Non-alcoholic Fatty Liver Disease - metabolism
  • Non-alcoholic Fatty Liver Disease - physiopathology
  • Observations
  • Overweight - diet therapy
  • Overweight - immunology
  • Overweight - metabolism
  • Overweight - physiopathology
  • Physiological aspects
  • Proteolipids
  • Risk Factors
ispartof: Annual review of nutrition, 2016-07-17, Vol.36 (1), p.275-299
description: Citrus flavonoids are polyphenolic compounds with significant biological properties. This review summarizes recent advances in understanding the ability of citrus flavonoids to modulate lipid metabolism, other metabolic parameters related to the metabolic syndrome, and atherosclerosis. Citrus flavonoids, including naringenin, hesperitin, nobiletin, and tangeretin, have emerged as potential therapeutics for the treatment of metabolic dysregulation. Epidemiological studies reveal an association between the intake of citrus flavonoid-containing foods and a decreased incidence of cardiovascular disease. Studies in cell culture and animal models, as well as a limited number of clinical studies, reveal the lipid-lowering, insulin-sensitizing, antihypertensive, and anti-inflammatory properties of citrus flavonoids. In animal models, supplementation of rodent diets with citrus flavonoids prevents hepatic steatosis, dyslipidemia, and insulin resistance primarily through inhibition of hepatic fatty acid synthesis and increased fatty acid oxidation. Citrus flavonoids blunt the inflammatory response in metabolically important tissues including liver, adipose, kidney, and the aorta. The mechanisms underlying flavonoid-induced metabolic regulation have not been completely established, although several potential targets have been identified. In mouse models, citrus flavonoids show marked suppression of atherogenesis through improved metabolic parameters as well as through direct impact on the vessel wall. Recent studies support a role for citrus flavonoids in the treatment of dyslipidemia, insulin resistance, hepatic steatosis, obesity, and atherosclerosis. Larger human studies examining dose, bioavailability, efficacy, and safety are required to promote the development of these promising therapeutic agents.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0199-9885
fulltext: fulltext
issn:
  • 0199-9885
  • 1545-4312
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.720725
LOCALfalse
PrimoNMBib
record
control
sourceidgale_cross
recordidTN_cdi_pubmed_primary_27146015
sourceformatXML
sourcesystemPC
galeidA458634594
sourcerecordidA458634594
originalsourceidFETCH-LOGICAL-a3481-41c732cc53b90229a3f40215351007c004827eb16148dc236d7b554080182b803
addsrcrecordideNqVkV1rFDEYhYModlv9CzLojTdT33zNZLzRZWlV2CKIXodMJlMjmWRNMpX--2aYVVC8aAkkITznvCcchF5iOMeYNW-U93M0N7Wfc6yhxS3mNfByEY_QBnPGa0YxeYw2gLuu7oTgJ-g0pR8A0FFKn6IT0hYfwHyDrnY2xzlVl07dBB_skCqVqi_menYqh5iqMFZ7ewiHGLKxvroyWfXB2TRVyg_VNn83MSTtlt2mZ-jJqFwyz4_nGfp2efF197Hef_7wabfd14oygWuGdUuJ1pz2HRDSKToyIJhTjgFaDcAEaU2PG8zEoAlthrbnnIEALEgvgJ6h16tvifVzNinLySZtnFPehDlJLIC3TdMwUtBXK3qtnJHWjyFHpRdcbhkXDWW8Y4U6_w9V1mAmq4M3oy3vfwnergJdPp6iGeUh2knFW4lBLi3JY0tyaUmuLcm1pSJ-cYw_95MZ_kh_11KA9_-4a5tVtsGXWNbdb8a71WJhlCuUNb_SQ1LeAVaBuoI
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1805766642
display
typearticle
titleCitrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis
sourceAlma/SFX Local Collection
creatorMulvihill, Erin E ; Burke, Amy C ; Huff, Murray W
creatorcontribMulvihill, Erin E ; Burke, Amy C ; Huff, Murray W
descriptionCitrus flavonoids are polyphenolic compounds with significant biological properties. This review summarizes recent advances in understanding the ability of citrus flavonoids to modulate lipid metabolism, other metabolic parameters related to the metabolic syndrome, and atherosclerosis. Citrus flavonoids, including naringenin, hesperitin, nobiletin, and tangeretin, have emerged as potential therapeutics for the treatment of metabolic dysregulation. Epidemiological studies reveal an association between the intake of citrus flavonoid-containing foods and a decreased incidence of cardiovascular disease. Studies in cell culture and animal models, as well as a limited number of clinical studies, reveal the lipid-lowering, insulin-sensitizing, antihypertensive, and anti-inflammatory properties of citrus flavonoids. In animal models, supplementation of rodent diets with citrus flavonoids prevents hepatic steatosis, dyslipidemia, and insulin resistance primarily through inhibition of hepatic fatty acid synthesis and increased fatty acid oxidation. Citrus flavonoids blunt the inflammatory response in metabolically important tissues including liver, adipose, kidney, and the aorta. The mechanisms underlying flavonoid-induced metabolic regulation have not been completely established, although several potential targets have been identified. In mouse models, citrus flavonoids show marked suppression of atherogenesis through improved metabolic parameters as well as through direct impact on the vessel wall. Recent studies support a role for citrus flavonoids in the treatment of dyslipidemia, insulin resistance, hepatic steatosis, obesity, and atherosclerosis. Larger human studies examining dose, bioavailability, efficacy, and safety are required to promote the development of these promising therapeutic agents.
identifier
0ISSN: 0199-9885
1EISSN: 1545-4312
2DOI: 10.1146/annurev-nutr-071715-050718
3PMID: 27146015
languageeng
publisherUnited States: Annual Reviews
subjectadipose tissue ; Animals ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Anti-Obesity Agents - therapeutic use ; Antioxidants - therapeutic use ; Atherosclerosis ; Atherosclerosis - epidemiology ; Atherosclerosis - etiology ; Atherosclerosis - prevention & control ; Bioflavonoids ; Blood lipoproteins ; Citrus ; Citrus - chemistry ; citrus flavonoids ; Citrus fruits ; Diabetes Mellitus, Type 2 - diet therapy ; Diabetes Mellitus, Type 2 - immunology ; Diabetes Mellitus, Type 2 - metabolism ; Diabetes Mellitus, Type 2 - physiopathology ; Dietary Supplements ; Flavones ; Flavonoids ; Flavonoids - therapeutic use ; glucose metabolism ; Health aspects ; Humans ; Hyperlipidemias - diet therapy ; Hyperlipidemias - immunology ; Hyperlipidemias - metabolism ; Hyperlipidemias - physiopathology ; Hypolipidemic Agents - therapeutic use ; inflammation ; Insulin Resistance ; lipid metabolism ; Lipoproteins ; Lipoproteins - blood ; Lipoproteins - metabolism ; Metabolism ; Non-alcoholic Fatty Liver Disease - diet therapy ; Non-alcoholic Fatty Liver Disease - immunology ; Non-alcoholic Fatty Liver Disease - metabolism ; Non-alcoholic Fatty Liver Disease - physiopathology ; Observations ; Overweight - diet therapy ; Overweight - immunology ; Overweight - metabolism ; Overweight - physiopathology ; Physiological aspects ; Proteolipids ; Risk Factors
ispartofAnnual review of nutrition, 2016-07-17, Vol.36 (1), p.275-299
rights
0Copyright © 2016 by Annual Reviews. All rights reserved 2016
1COPYRIGHT 2016 Annual Reviews, Inc.
lds50peer_reviewed
citedbyFETCH-LOGICAL-a3481-41c732cc53b90229a3f40215351007c004827eb16148dc236d7b554080182b803
citesFETCH-LOGICAL-a3481-41c732cc53b90229a3f40215351007c004827eb16148dc236d7b554080182b803
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27146015$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Mulvihill, Erin E
1Burke, Amy C
2Huff, Murray W
title
0Citrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis
1Annual review of nutrition
addtitleAnnu Rev Nutr
descriptionCitrus flavonoids are polyphenolic compounds with significant biological properties. This review summarizes recent advances in understanding the ability of citrus flavonoids to modulate lipid metabolism, other metabolic parameters related to the metabolic syndrome, and atherosclerosis. Citrus flavonoids, including naringenin, hesperitin, nobiletin, and tangeretin, have emerged as potential therapeutics for the treatment of metabolic dysregulation. Epidemiological studies reveal an association between the intake of citrus flavonoid-containing foods and a decreased incidence of cardiovascular disease. Studies in cell culture and animal models, as well as a limited number of clinical studies, reveal the lipid-lowering, insulin-sensitizing, antihypertensive, and anti-inflammatory properties of citrus flavonoids. In animal models, supplementation of rodent diets with citrus flavonoids prevents hepatic steatosis, dyslipidemia, and insulin resistance primarily through inhibition of hepatic fatty acid synthesis and increased fatty acid oxidation. Citrus flavonoids blunt the inflammatory response in metabolically important tissues including liver, adipose, kidney, and the aorta. The mechanisms underlying flavonoid-induced metabolic regulation have not been completely established, although several potential targets have been identified. In mouse models, citrus flavonoids show marked suppression of atherogenesis through improved metabolic parameters as well as through direct impact on the vessel wall. Recent studies support a role for citrus flavonoids in the treatment of dyslipidemia, insulin resistance, hepatic steatosis, obesity, and atherosclerosis. Larger human studies examining dose, bioavailability, efficacy, and safety are required to promote the development of these promising therapeutic agents.
subject
0adipose tissue
1Animals
2Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
3Anti-Obesity Agents - therapeutic use
4Antioxidants - therapeutic use
5Atherosclerosis
6Atherosclerosis - epidemiology
7Atherosclerosis - etiology
8Atherosclerosis - prevention & control
9Bioflavonoids
10Blood lipoproteins
11Citrus
12Citrus - chemistry
13citrus flavonoids
14Citrus fruits
15Diabetes Mellitus, Type 2 - diet therapy
16Diabetes Mellitus, Type 2 - immunology
17Diabetes Mellitus, Type 2 - metabolism
18Diabetes Mellitus, Type 2 - physiopathology
19Dietary Supplements
20Flavones
21Flavonoids
22Flavonoids - therapeutic use
23glucose metabolism
24Health aspects
25Humans
26Hyperlipidemias - diet therapy
27Hyperlipidemias - immunology
28Hyperlipidemias - metabolism
29Hyperlipidemias - physiopathology
30Hypolipidemic Agents - therapeutic use
31inflammation
32Insulin Resistance
33lipid metabolism
34Lipoproteins
35Lipoproteins - blood
36Lipoproteins - metabolism
37Metabolism
38Non-alcoholic Fatty Liver Disease - diet therapy
39Non-alcoholic Fatty Liver Disease - immunology
40Non-alcoholic Fatty Liver Disease - metabolism
41Non-alcoholic Fatty Liver Disease - physiopathology
42Observations
43Overweight - diet therapy
44Overweight - immunology
45Overweight - metabolism
46Overweight - physiopathology
47Physiological aspects
48Proteolipids
49Risk Factors
issn
00199-9885
11545-4312
fulltexttrue
rsrctypearticle
creationdate2016
recordtypearticle
recordideNqVkV1rFDEYhYModlv9CzLojTdT33zNZLzRZWlV2CKIXodMJlMjmWRNMpX--2aYVVC8aAkkITznvCcchF5iOMeYNW-U93M0N7Wfc6yhxS3mNfByEY_QBnPGa0YxeYw2gLuu7oTgJ-g0pR8A0FFKn6IT0hYfwHyDrnY2xzlVl07dBB_skCqVqi_menYqh5iqMFZ7ewiHGLKxvroyWfXB2TRVyg_VNn83MSTtlt2mZ-jJqFwyz4_nGfp2efF197Hef_7wabfd14oygWuGdUuJ1pz2HRDSKToyIJhTjgFaDcAEaU2PG8zEoAlthrbnnIEALEgvgJ6h16tvifVzNinLySZtnFPehDlJLIC3TdMwUtBXK3qtnJHWjyFHpRdcbhkXDWW8Y4U6_w9V1mAmq4M3oy3vfwnergJdPp6iGeUh2knFW4lBLi3JY0tyaUmuLcm1pSJ-cYw_95MZ_kh_11KA9_-4a5tVtsGXWNbdb8a71WJhlCuUNb_SQ1LeAVaBuoI
startdate20160717
enddate20160717
creator
0Mulvihill, Erin E
1Burke, Amy C
2Huff, Murray W
general
0Annual Reviews
1Annual Reviews, Inc
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
97X8
sort
creationdate20160717
titleCitrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis
authorMulvihill, Erin E ; Burke, Amy C ; Huff, Murray W
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-a3481-41c732cc53b90229a3f40215351007c004827eb16148dc236d7b554080182b803
rsrctypearticles
prefilterarticles
languageeng
creationdate2016
topic
0adipose tissue
1Animals
2Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
3Anti-Obesity Agents - therapeutic use
4Antioxidants - therapeutic use
5Atherosclerosis
6Atherosclerosis - epidemiology
7Atherosclerosis - etiology
8Atherosclerosis - prevention & control
9Bioflavonoids
10Blood lipoproteins
11Citrus
12Citrus - chemistry
13citrus flavonoids
14Citrus fruits
15Diabetes Mellitus, Type 2 - diet therapy
16Diabetes Mellitus, Type 2 - immunology
17Diabetes Mellitus, Type 2 - metabolism
18Diabetes Mellitus, Type 2 - physiopathology
19Dietary Supplements
20Flavones
21Flavonoids
22Flavonoids - therapeutic use
23glucose metabolism
24Health aspects
25Humans
26Hyperlipidemias - diet therapy
27Hyperlipidemias - immunology
28Hyperlipidemias - metabolism
29Hyperlipidemias - physiopathology
30Hypolipidemic Agents - therapeutic use
31inflammation
32Insulin Resistance
33lipid metabolism
34Lipoproteins
35Lipoproteins - blood
36Lipoproteins - metabolism
37Metabolism
38Non-alcoholic Fatty Liver Disease - diet therapy
39Non-alcoholic Fatty Liver Disease - immunology
40Non-alcoholic Fatty Liver Disease - metabolism
41Non-alcoholic Fatty Liver Disease - physiopathology
42Observations
43Overweight - diet therapy
44Overweight - immunology
45Overweight - metabolism
46Overweight - physiopathology
47Physiological aspects
48Proteolipids
49Risk Factors
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Mulvihill, Erin E
1Burke, Amy C
2Huff, Murray W
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8MEDLINE - Academic
jtitleAnnual review of nutrition
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Mulvihill, Erin E
1Burke, Amy C
2Huff, Murray W
formatjournal
genrearticle
ristypeJOUR
atitleCitrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis
jtitleAnnual review of nutrition
addtitleAnnu Rev Nutr
date2016-07-17
risdate2016
volume36
issue1
spage275
epage299
pages275-299
issn0199-9885
eissn1545-4312
abstractCitrus flavonoids are polyphenolic compounds with significant biological properties. This review summarizes recent advances in understanding the ability of citrus flavonoids to modulate lipid metabolism, other metabolic parameters related to the metabolic syndrome, and atherosclerosis. Citrus flavonoids, including naringenin, hesperitin, nobiletin, and tangeretin, have emerged as potential therapeutics for the treatment of metabolic dysregulation. Epidemiological studies reveal an association between the intake of citrus flavonoid-containing foods and a decreased incidence of cardiovascular disease. Studies in cell culture and animal models, as well as a limited number of clinical studies, reveal the lipid-lowering, insulin-sensitizing, antihypertensive, and anti-inflammatory properties of citrus flavonoids. In animal models, supplementation of rodent diets with citrus flavonoids prevents hepatic steatosis, dyslipidemia, and insulin resistance primarily through inhibition of hepatic fatty acid synthesis and increased fatty acid oxidation. Citrus flavonoids blunt the inflammatory response in metabolically important tissues including liver, adipose, kidney, and the aorta. The mechanisms underlying flavonoid-induced metabolic regulation have not been completely established, although several potential targets have been identified. In mouse models, citrus flavonoids show marked suppression of atherogenesis through improved metabolic parameters as well as through direct impact on the vessel wall. Recent studies support a role for citrus flavonoids in the treatment of dyslipidemia, insulin resistance, hepatic steatosis, obesity, and atherosclerosis. Larger human studies examining dose, bioavailability, efficacy, and safety are required to promote the development of these promising therapeutic agents.
copUnited States
pubAnnual Reviews
pmid27146015
doi10.1146/annurev-nutr-071715-050718